# Dalton Bioanalytics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dalton-bioanalytics

- Industry: Biotechnology
- Headquarters: Los Angeles, US
- Website: www.daltonbioanalytics.com
- Latest round: Seed (Aug 20, 2019)
- Investors on record: 2

## About

Dalton Bioanalytics Inc. develops innovative technology solutions that enhance operational efficiency across various sectors, including healthcare, finance, and retail, utilizing advanced data analytics and workflow management software applications.Dalton Bioanalytics Inc. operates in the field of bioanalytics, focusing on technology solutions that optimize operations. Founded by Austin Quach and Seungjun Yeo, the company's headquarters is located in Los Angeles, US. In August 2019, Dalton Bioanalytics Inc. raised an undisclosed amount in SEED funding from IndieBio and SOSV, marking their sole deal to date. Seungjun Yeo currently serves as the CEO.The company specializes in technology solutions designed to enhance operational efficiency across various sectors. Their core product offerings include a suite of software applications that streamline workflow management, enhance data analytics, and improve customer relationship management. Released over the past five years, these products cater to industries such as healthcare, finance, and retail, aiming to solve challenges related to process optimization and data-driven decision-making. The company serves a diverse client base, including small to medium-sized enterprises and large corporations, particularly in North America and Europe, with a focus on ease of integration and user-friendly interfaces to ensure widespread adoption among employees and management alike.The company's revenue model is primarily based on a subscription-based framework, allowing clients to access their software solutions on a recurring basis. This structure involves monthly or annual fees that vary based on the level of service and number of users. Key flagship products are bundled into different pricing tiers, providing companies with options that meet their specific operational needs. Additionally, the company engages in B2B transactions, partnering with distributors and resellers to expand its reach in international markets while also facilitating direct sales to end-users to ensure comprehensive service delivery across its offerings.Dalton Bioanalytics Inc. plans to enhance its product line with the introduction of new software solutions aimed at improving user functionality and expanding features within the next year. The company is also focusing on market expansion into Europe and Asia by the end of 2022. The recent SEED funding raised in August 2019 will support these initiatives and the development of new products and features.

## Funding rounds

- Seed, Aug 20, 2019 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed